Latest Breaking News On - Patent protected - Page 1 : comparemela.com

The RefluxStop device prevents the regurgitation of stomach fluid into the esophagus and addresses the limitations of proton pump inhibitors (PPIs) and existing surgical methods and devices for treating acid reflux disease. SAN ANTONIO, June 16, 2022 /PRNewswire/ - Frost & Sullivan recently assessed the European gastroesophageal reflux disease (GERD) treatment industry and, based on its findings, recognizes Implantica with the 2022 European Technology Innovation Leadership Award for its GERD therapy device. The company developed the RefluxStop device, a CE-marked, first-of-its-kind single-use sterile medical implant, for acid reflux treatment. The device prevents the regurgitation of stomach fluid into the esophagus and addresses the limitations of commonly used drug treatment, Proton Pump Inhibitors (PPIs) and current surgical methods for treating acid reflux disease. The RefluxStop device is placed outside of the top part of the stomach (fundus wall) during laparoscopic surgery,

United kingdomJuanita eberhartBianca torresNeeraj nitin jadhavImplantica refluxstopAmerican college of gastroenterologyEuropean technology innovation leadership awardTechnology innovation leadership awardProton pump inhibitorsAmerican collegeNitin jadhavIndustry analystSullivan best practices awardsMega trendsNasdaq first north premier growth marketThe refluxstop device prevents regurgitation of stomach fluid into esophagus and addresses limitations proton pump inhibitors ppis existing surgical methods devices for treating acid reflux disease san antonio